Article info
PDFClinical science
UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice
- Correspondence to Dr Cecilia S Lee, Department of Ophthalmology, University of Washington, Box 359608, 325 Ninth Avenue, Seattle, WA 98104, USA; leecs2{at}uw.edu, jung.cecilia{at}gmail.com
Citation
UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice
Publication history
- Received October 19, 2016
- Revised March 7, 2017
- Accepted April 6, 2017
- First published May 6, 2017.
Online issue publication
November 23, 2017
Article Versions
- Previous version (6 May 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.